Fig. 2From: A real-world study on diagnosis and prognosis of light-chain cardiac amyloidosis in Southern ChinaKaplan–Meier survival curves demonstrating differences in overall survival (months). a The median survival time of Al-CA patients receiving chemotherapy was significantly longer than that of patients receiving palliative treatment (13.00 vs 6.00, log-rank test, p = 0.004). b In patients with NYHAI-III, receiving chemotherapy improved outcome significantly (15.00 vs 10.00, p = 0.031). c In AL-CA group, survival time was significantly higher in patients who were HFpEF (LVEF < 50%) (13.00 vs 4.00, p = 0.001). (D)Median survival time of patients with NYHA III-IV was shorter than NYHA I-II group (6.00 vs 17.00, p = 0.006)Back to article page